Chase Feiger - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Chase Feiger's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Chase Feiger
Verified
Contributor, Forbes
Beats
Lifestyle, Fashion, and Politics.
Content
By Chase Feiger| Forbes Verified Takeda’s (NYSE: TAK) (TSE:4502) plasma-derived therapies (PDT) business, led by Giles Platford, president of Takeda’s Plasma-Derived Therapies Business Unit and chair of the Plasma Protein Therapeutics Association global executive board of directors, tackles complex logistical and economic challenges, collecting about 15 million liters of blood plasma annually from millions of donations and transforming it into medicines.
By Chase Feiger| Forbes Verified In the global fight against HIV, a twice-yearly injection could represent a seismic shift in prevention efforts. Lenacapavir, Gilead Sciences’ (NASDAQ: GILD) innovative therapy for HIV pre-exposure prophylaxis (PrEP), is not only a breakthrough in clinical efficacy but also a model for advancing equitable healthcare access.
By Chase Feiger| Forbes Verified Takeda’s (NYSE: TAK) (TSE:4502) plasma-derived therapies (PDT) business, led by Giles Platford, president of Takeda’s Plasma-Derived Therapies Business Unit and chair of the Plasma Protein Therapeutics Association global executive board of directors, tackles complex logistical and economic challenges, collecting about 15 million liters of blood plasma annually from millions of donations and transforming it into medicines.
Company Info
Forbes
United States, United States